Craig Venter is retiring from Human Longevity to return to the research institution that bears his name, the San Diego Union-Tribune reports.
Researchers detected excess genetic risk and/or misclassification when profiling ClinVar variants in ACMG-59 and OrphaNet genes using genome and exome sequences.
Craig Venter and Human Longevity aim to uncover disease through sequencing and other tests to increase lifespans, CNBC says.
The team found that constrained regions of the noncoding genome are up to 52-fold enriched for known pathogenic variants as compared to unconstrained regions.
Craig Venter says his company has uncovered disease in people who otherwise appeared healthy, HealthcareITNews reports.
Researchers have argued that the facial prediction claims are overblown and serve Human Longevity's financial interests in proprietary genomic databases.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.